The SCN2A Gene Early Infantile Epileptic Encephalopathy Type 11 Genetic Test is a specialized diagnostic tool used to identify mutations in the SCN2A gene, which are linked to Early Infantile Epileptic Encephalopathy Type 11 (EIEE11). This condition is a severe form of epilepsy that begins in infancy and is characterized by frequent seizures and significant developmental delays. The test is crucial for early diagnosis and management of the condition, allowing healthcare providers to tailor treatment plans to the individual needs of the patient.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing the genetic material for specific mutations in the SCN2A gene. The accuracy and reliability of the test make it a valuable resource for families seeking answers to complex neurological conditions.
The cost of the SCN2A Gene Early Infantile Epileptic Encephalopathy Type 11 Genetic Test is 4400 AED. While the price may seem significant, the insights provided by the test can be invaluable in guiding the clinical management of affected individuals, potentially improving outcomes and quality of life.
The PLCB1 gene plays a crucial role in brain development and function. Mutations in this gene have been linked to early infantile epileptic encephalopathy type 12 (EIEE12), a severe neurological disorder. This condition is characterized by early-onset seizures, developmental delay, and sometimes other neurological complications. Genetic testing for mutations in the PLCB1 gene is essential for diagnosing EIEE12, guiding treatment options, and providing genetic counseling for affected families.
At DNA Labs UAE, a specialized genetic test is available for identifying mutations in the PLCB1 gene associated with early infantile epileptic encephalopathy type 12. The test involves analyzing the patient's DNA to detect specific genetic alterations that cause the condition. This precise genetic testing is a crucial step in the diagnosis and management of EIEE12, allowing for tailored treatment plans and support for patients and their families.
The cost of the PLCB1 gene test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis necessary to identify the genetic underpinnings of EIEE12, providing invaluable information for affected individuals and their healthcare providers. Through this testing, DNA Labs UAE offers hope and direction for families navigating the challenges of early infantile epileptic encephalopathy type 12.
The SCN8A gene early infantile epileptic encephalopathy type 13 genetic test is a specialized diagnostic tool aimed at identifying mutations in the SCN8A gene, which have been linked to a severe form of epilepsy known as early infantile epileptic encephalopathy type 13 (EIEE13). This condition is characterized by frequent seizures that begin in the first months of life, often accompanied by developmental delays and other neurological issues. The SCN8A gene plays a crucial role in the functioning of brain cells, and mutations in this gene can disrupt the normal electrical activity in the brain, leading to epilepsy.
The test is available at DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates. The cost of the test is 4400 AED, which reflects the specialized nature of the analysis and the sophisticated technology employed to accurately detect mutations in the SCN8A gene. By identifying these genetic mutations, the test can provide crucial information for the diagnosis and management of early infantile epileptic encephalopathy type 13, enabling healthcare providers to tailor treatment plans to the specific needs of their patients. This can include targeted therapies that may be more effective based on the patient's genetic makeup, thereby improving outcomes and enhancing the quality of life for those affected by this challenging condition.
The KCNT1 gene is associated with early infantile epileptic encephalopathy type 14 (EIEE14), a severe form of epilepsy that begins in infancy. This condition is characterized by frequent seizures and significant developmental delays, impacting an individual's quality of life. The KCNT1 gene plays a crucial role in the proper functioning of neurons, and mutations in this gene disrupt the normal electrical activity in the brain, leading to epilepsy.
Genetic testing for mutations in the KCNT1 gene is essential for the accurate diagnosis and management of EIEE14. DNA Labs UAE offers a comprehensive genetic test specifically designed to identify mutations in the KCNT1 gene. The test is a valuable tool for families seeking answers to their child’s severe epilepsy, providing crucial information that can guide treatment decisions and genetic counseling.
The cost of the KCNT1 gene test at DNA Labs UAE is 4400 AED. This investment can be invaluable for affected families, as it not only helps in confirming the diagnosis but also assists in understanding the risk of passing the condition to future generations. Additionally, knowing the specific genetic mutation can open up opportunities for targeted therapies and interventions, potentially improving the quality of life for those affected by EIEE14.
The ST3GAL3 gene is associated with early infantile epileptic encephalopathy type 15 (EIEE15), a rare and severe neurological disorder. This condition is characterized by frequent seizures that begin in infancy, developmental delay, and other possible neurological impairments. The ST3GAL3 gene plays a crucial role in brain development and function, and mutations in this gene are responsible for the disorder.
DNA Labs UAE offers a genetic test specifically designed to detect mutations in the ST3GAL3 gene, aiding in the diagnosis of early infantile epileptic encephalopathy type 15. The test is a vital tool for families seeking answers to developmental and epileptic concerns in infants, providing them with crucial information for medical management and treatment planning.
The cost of the ST3GAL3 gene test at DNA Labs UAE is 4400 AED. This investment allows for a comprehensive analysis of the gene in question, offering insights that can significantly impact the clinical approach to managing and supporting affected individuals. Early diagnosis through this genetic testing can facilitate timely interventions, potentially improving outcomes and quality of life for those diagnosed with EIEE15.
The TBC1D24 gene is associated with early infantile epileptic encephalopathy type 16 (EIEE16), a severe neurological condition that manifests early in infancy. This condition is characterized by frequent seizures that are resistant to treatment, developmental delay, and sometimes additional neurological symptoms. The TBC1D24 gene plays a crucial role in brain development and function, and mutations in this gene are known to disrupt these processes, leading to the symptoms observed in EIEE16.
To diagnose this condition, genetic testing is essential. DNA Labs UAE offers a specific genetic test targeting the TBC1D24 gene to confirm the presence of mutations that cause early infantile epileptic encephalopathy type 16. This test is crucial for the accurate diagnosis of EIEE16, enabling appropriate management and treatment strategies to be implemented for affected individuals. The cost of the TBC1D24 gene test at DNA Labs UAE is 4400 AED.
This test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing the TBC1D24 gene for any mutations. The results can provide valuable information for families regarding prognosis, potential treatment options, and the risk of recurrence in future pregnancies. It is also a step forward in understanding the genetic basis of the condition, contributing to ongoing research and potential future therapies.
The GNAO1 gene is crucial for proper brain function and development. Mutations in this gene can lead to a rare but severe condition known as Early Infantile Epileptic Encephalopathy Type 17 (EIEE17). This condition is characterized by frequent seizures that begin in the first few months of life, developmental delays, and other neurological issues. Genetic testing for mutations in the GNAO1 gene is essential for diagnosing EIEE17, guiding treatment options, and offering genetic counseling for families.
DNA Labs UAE offers a comprehensive genetic test to detect mutations in the GNAO1 gene, aiding in the diagnosis of Early Infantile Epileptic Encephalopathy Type 17. The test is a crucial step for families seeking answers about this challenging condition. The cost of the test is 4400 AED, reflecting the specialized analysis required to accurately identify the presence of mutations in the GNAO1 gene. By opting for this test, families can gain valuable insights into their child's condition, enabling better management and care strategies tailored to their specific needs.
The GABRA1 gene is associated with early infantile epileptic encephalopathy type 19 (EIEE19), a severe form of epilepsy that emerges in infancy. This condition is characterized by frequent seizures and significant developmental delays, affecting both cognitive and motor skills. The GABRA1 gene plays a crucial role in the functioning of GABA receptors, which are essential for inhibiting nerve transmission in the brain, thus preventing excessive neuronal activity that can lead to seizures.
Given the critical nature of accurately diagnosing EIEE19 for effective management and treatment, genetic testing for mutations in the GABRA1 gene is a valuable diagnostic tool. DNA Labs UAE offers a comprehensive genetic test specifically designed to identify mutations in the GABRA1 gene that are linked to early infantile epileptic encephalopathy type 19. The test is priced at 4400 AED and involves analyzing the patient's DNA to detect any genetic alterations that may contribute to the condition.
Conducting this test can provide crucial information for families and healthcare providers, enabling them to understand the genetic underpinnings of the disorder, anticipate its progression, and tailor treatment plans accordingly. It is an essential step for those affected by or at risk of EIEE19, offering hope for better management of this challenging condition.
The CDKL5 gene early infantile epileptic encephalopathy type 2 genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the CDKL5 gene. This gene is crucial for normal brain development and function. Mutations in the CDKL5 gene are associated with early infantile epileptic encephalopathy type 2 (EIEE2), a severe neurological condition that manifests in the first few months of life with frequent seizures, developmental delays, and, in some cases, features of autism spectrum disorders. The test, priced at 4400 AED, involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any abnormalities in the CDKL5 gene. This genetic testing is essential for the accurate diagnosis and management of the condition, allowing for tailored treatment plans and support for affected individuals and their families.
The PIGA gene test for early infantile epileptic encephalopathy type 20 (EIEE20) is a specialized genetic examination designed to identify mutations in the PIGA gene, which are associated with this severe neurological condition. EIEE20 is characterized by early onset of frequent seizures, developmental delay, and various other neurological impairments. The test aims to provide a definitive diagnosis by analyzing the patient's DNA for specific genetic abnormalities within the PIGA gene that are known to cause the disorder.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers families and physicians critical information that can guide treatment decisions and prognosis. Understanding the genetic underpinnings of the condition can also be beneficial for genetic counseling, particularly for families considering future pregnancies.
The cost of the PIGA gene test for EIEE20 at DNA Labs UAE is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the PIGA gene. For families facing the challenges of EIEE20, this test represents a crucial step towards a clearer understanding of the condition and the potential for targeted therapeutic strategies.
